Generex Biotechnology CorpGenerex Biotechnology Corp - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This ESG rating includes 17 UN SDGs including: 'Quality Education', 'Responsible Production & Consumption' and 'Partnerships for the Goals'. The Sustainability assessment for Generex Biotechnology Corp represents its transparency towards the United Nations SDGs. Comprehensive ESG assessment of Generex Biotechnology Corp can be accessed by registering for free.

Generex Biotechnology Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.

SDG Transparency Score for Generex Biotechnology Corp 

0.0

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Generex Biotechnology Corp 
0.0

Environmental

0.0

Social

0.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1967Hospira Inc
0.3
Low
1967PRA Health Sciences Inc
0.3
Low
1970Generex Biotechnology Corp
0.0
Low
1970CSPC Innovation Pharmaceutical Co Ltd
0.0
Low
1970CTC Bio Inc
0.0
Low
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Generex Biotechnology Corp have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Generex Biotechnology Corp report the average age of the workforce?

LockedSign up for free to unlock

Does Generex Biotechnology Corp reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose cybersecurity risks?

LockedSign up for free to unlock

Does Generex Biotechnology Corp offer flexible work?

LockedSign up for free to unlock

Does Generex Biotechnology Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Generex Biotechnology Corp conduct supply chain audits?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Generex Biotechnology Corp conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose water use targets?

LockedSign up for free to unlock

Does Generex Biotechnology Corp have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Generex Biotechnology Corp have a product recall in the last two years?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose incidents of discrimination?

LockedSign up for free to unlock

Does Generex Biotechnology Corp allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Generex Biotechnology Corp issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose parental leave metrics?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Generex Biotechnology Corp support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Generex Biotechnology Corp reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Generex Biotechnology Corp involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose its waste policy?

LockedSign up for free to unlock

Does Generex Biotechnology Corp report according to TCFD requirements?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose energy use targets?

LockedSign up for free to unlock

Does Generex Biotechnology Corp disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Generex Biotechnology Corp have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Generex Biotechnology Corp
These potential risks are based on the size, segment and geographies of the company.

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Sorry!

Failed to process!